484 related articles for article (PubMed ID: 17891838)
21. Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma.
Berruti A; Grisanti S; Pulzer A; Claps M; Daffara F; Loli P; Mannelli M; Boscaro M; Arvat E; Tiberio G; Hahner S; Zaggia B; Porpiglia F; Volante M; Fassnacht M; Terzolo M
J Clin Endocrinol Metab; 2017 Apr; 102(4):1358-1365. PubMed ID: 28324035
[TBL] [Abstract][Full Text] [Related]
22. Practical treatment using mitotane for adrenocortical carcinoma.
Terzolo M; Zaggia B; Allasino B; De Francia S
Curr Opin Endocrinol Diabetes Obes; 2014 Jun; 21(3):159-65. PubMed ID: 24732405
[TBL] [Abstract][Full Text] [Related]
23. The next generation of therapies for adrenocortical cancers.
Kirschner LS
Trends Endocrinol Metab; 2012 Jul; 23(7):343-50. PubMed ID: 22626690
[TBL] [Abstract][Full Text] [Related]
24. Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis.
Tang Y; Liu Z; Zou Z; Liang J; Lu Y; Zhu Y
Biomed Res Int; 2018; 2018():9362108. PubMed ID: 29967789
[TBL] [Abstract][Full Text] [Related]
25. [Practical use of o,p'DDD in adrenocortical carcinoma].
Bacchetta J; Droz JP
Bull Cancer; 2005 Mar; 92(3):273-9. PubMed ID: 15820922
[TBL] [Abstract][Full Text] [Related]
26. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane.
Grubbs EG; Callender GG; Xing Y; Perrier ND; Evans DB; Phan AT; Lee JE
Ann Surg Oncol; 2010 Jan; 17(1):263-70. PubMed ID: 19851811
[TBL] [Abstract][Full Text] [Related]
27. New perspectives for mitotane treatment of adrenocortical carcinoma.
Puglisi S; Calabrese A; Basile V; Pia A; Reimondo G; Perotti P; Terzolo M
Best Pract Res Clin Endocrinol Metab; 2020 May; 34(3):101415. PubMed ID: 32179008
[TBL] [Abstract][Full Text] [Related]
28. Mitotane With or Without Cisplatin and Etoposide for Patients with a High Risk of Recurrence in Stages 1-3 Adrenocortical Cancer After Surgery.
Sarvestani AL; Gregory SN; Teke ME; Terzolo M; Berruti A; Hernandez JM; Habra MA
Ann Surg Oncol; 2023 Feb; 30(2):680-682. PubMed ID: 36305989
[No Abstract] [Full Text] [Related]
29. Emerging drugs for adrenocortical carcinoma.
Berruti A; Ferrero A; Sperone P; Daffara F; Reimondo G; Papotti M; Dogliotti L; Angeli A; Terzolo M
Expert Opin Emerg Drugs; 2008 Sep; 13(3):497-509. PubMed ID: 18764725
[TBL] [Abstract][Full Text] [Related]
30. Mitotane serum level analysis; good agreement between two different assays.
Hermsen IG; den Hartigh J; Haak HR
Clin Endocrinol (Oxf); 2010 Aug; 73(2):271-2. PubMed ID: 20105188
[No Abstract] [Full Text] [Related]
31. Normal adrenal function in an infant following a pregnancy complicated by maternal adrenal cortical carcinoma and mitotane exposure.
Kojori F; Cronin CM; Salamon E; Burym C; Sellers EA
J Pediatr Endocrinol Metab; 2011; 24(3-4):203-4. PubMed ID: 21648293
[TBL] [Abstract][Full Text] [Related]
32. High-Dose Mitotane-Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma.
Pape E; Feliu C; Yéléhé-Okouma M; Colling N; Djerada Z; Gambier N; Weryha G; Scala-Bertola J
Oncologist; 2018 Mar; 23(3):389-390. PubMed ID: 29192018
[No Abstract] [Full Text] [Related]
33. Impact of standardised reporting in adrenocortical carcinoma: a single centre clinicopathological review.
Advani A; Vaikkakara S; Gill MS; Arun CS; Pearce SH; Ball SG; James RA; Lennard TW; Bliss RD; Quinton R; Johnson SJ
J Clin Pathol; 2008 Aug; 61(8):939-44. PubMed ID: 18515402
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma.
Fassnacht M; Hahner S; Polat B; Koschker AC; Kenn W; Flentje M; Allolio B
J Clin Endocrinol Metab; 2006 Nov; 91(11):4501-4. PubMed ID: 16895957
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant mitotane for adrenocortical cancer--a recurring controversy.
Huang H; Fojo T
J Clin Endocrinol Metab; 2008 Oct; 93(10):3730-2. PubMed ID: 18842984
[No Abstract] [Full Text] [Related]
36. Mitotane treatment for adrenocortical carcinoma: an overview.
De Francia S; Ardito A; Daffara F; Zaggia B; Germano A; Berruti A; Di Carlo F
Minerva Endocrinol; 2012 Mar; 37(1):9-23. PubMed ID: 22382612
[TBL] [Abstract][Full Text] [Related]
37. Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm.
Abdel-Aziz TE; Rajeev P; Sadler G; Weaver A; Mihai R
World J Surg; 2015 May; 39(5):1268-73. PubMed ID: 25526921
[TBL] [Abstract][Full Text] [Related]
38. How is adrenocortical cancer being managed in the UK?
Aspinall SR; Imisairi AH; Bliss RD; Scott-Coombes D; Harrison BJ; Lennard TW
Ann R Coll Surg Engl; 2009 Sep; 91(6):489-93. PubMed ID: 19558758
[TBL] [Abstract][Full Text] [Related]
39. Medical therapy of adrenocortical tumors.
Kletter GB
Minerva Endocrinol; 2009 Jun; 34(2):149-59. PubMed ID: 19471239
[TBL] [Abstract][Full Text] [Related]
40. Comment--Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma?
Barzon L; Fallo F; Sonino N; Daniele O; Boscaro M
J Clin Endocrinol Metab; 1999 Apr; 84(4):1488-9. PubMed ID: 10199802
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]